The European Commission adopted in July 2011 boseprevir the treatment of chronic hepatitis C genotype 1 in combination with pegylated interferon alpha and ribavirin. Combination therapy for adult patients over 18 years of age with compensated liver disease who had not received previous treatment or who were not effective prior treatment with combination pegylated interferon and ribavirin. Chronic hepatitis C is a potentially serious viral infection of the liver, which affects about 4 million people across Europe.